OTCMKTS:POLXF Polydex Pharmaceuticals (POLXF) Stock Price, News & Analysis $1.99 +0.01 (+0.30%) As of 08/7/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Polydex Pharmaceuticals Stock (OTCMKTS:POLXF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get POLXF alerts:Sign Up Key Stats Today's Range$1.99▼$1.9950-Day Range$1.99▼$1.9952-Week Range$0.55▼$2.01Volume2,000 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPolydex Pharmaceuticals Ltd. is a development stage company, which engages in manufacturing of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry, and the development, manufacturing, and marketing of biotechnology-based products for the human pharmaceutical market. The firm focuses on Dextran and derivative products, including Iron Dextran and Dextran Sulphate and other specialty chemicals. The company was founded by Thomas C. Usher on June 14, 1979 and is headquartered in Toronto, Canada.Read More… Receive POLXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Polydex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address POLXF Stock News HeadlinesPolydex Pharmaceuticals Limited Shareholders Vote to Approve BioSpectra Inc. Business CombinationJuly 18, 2023 | finance.yahoo.comPolydex Pharmaceuticals Limited: Polydex Pharmaceuticals Issues First Quarter Financial ResultsJune 15, 2023 | finanznachrichten.deBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.May 11, 2025 | Golden Portfolio (Ad)Polydex Pharmaceuticals Limited and BioSpectra Inc. Announce Business CombinationApril 27, 2023 | finance.yahoo.comPolydex Pharmaceuticals Ltd.April 18, 2023 | barrons.comPolydex Pharmaceuticals GAAP EPS of -$0.09, revenue of $1.09MSeptember 17, 2022 | seekingalpha.comGlobal Computed Tomography (CT) Scanner Market to Reach $9.38 Billion by 2028 | Demand for AI based CT Scanner is On the RiseSeptember 16, 2022 | nz.finance.yahoo.comPolydex Pharmaceuticals LtdAugust 24, 2022 | reuters.comSee More Headlines POLXF Stock Analysis - Frequently Asked Questions How have POLXF shares performed this year? Polydex Pharmaceuticals' stock was trading at $1.9860 at the start of the year. Since then, POLXF stock has increased by 0.0% and is now trading at $1.9860. View the best growth stocks for 2025 here. How do I buy shares of Polydex Pharmaceuticals? Shares of POLXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/10/2025Fiscal Year End1/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Industrial inorganic chemicals Sub-IndustryN/A Current SymbolOTCMKTS:POLXF CIK317158 Webwww.polydex.com Phone(416) 755-2231FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$4.41 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:POLXF) was last updated on 5/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polydex Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Polydex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
